With respect to this, we have preliminary evidence that over-expression of RARα2 in a retinoid-responsive breast-cancer cell line inhibits ATRA-simulated activity of a RARE-containing reporter and suppresses ATRA-dependent induction of the retinoid targets, SMAD3 and β-catenin [52, 53]. Here, SMAD3 is linked to breast cancer.